Cartalax (chemical sequence: Ala-Glu-Asp or AED) is a synthetic tripeptide part of the “Khavinson Peptides” group, developed at the St. Petersburg Institute of Bioregulation and Gerontology (Khavinson et al., 2016). It is primarily marketed for its potential to support cartilage and joint health, particularly in the context of aging and degenerative conditions like osteoarthritis.

Reported Benefits & Mechanism of Action

Research, primarily from Russian institutes, suggests that Cartalax acts as a gene signaling molecule. It is hypothesized to penetrate cell membranes and interact with specific DNA sequences to modulate protein synthesis (Ashapkin et al., 2020).

• Chondrocyte Regulation: Chondrocytes are the cells responsible for maintaining the extracellular matrix (ECM) of cartilage (StatPearls, 2026). Cartalax is reported to stimulate the proliferation and functional activity of these cells, helping to maintain the balance between cartilage creation and destruction (Khavinson, 2023).
• Tissue Regeneration: In vitro studies have shown that Cartalax can stimulate cell renewal in various tissues. Specifically, it has been observed to modulate gene expression related to cellular differentiation and proliferation, which may assist in repairing “wear and tear” in joints (Chalisova et al., 2015).
• Anti-Aging Effects: By regulating gene expression, short peptides like Cartalax are claimed to increase the “physiological resource” of cells by up to 20–42%, potentially overcoming the Hayflick limit (the number of times a cell can divide) (Khavinson et al., 2016).

Research Data & Clinical Evidence

The data for Cartalax is largely concentrated in pre-clinical studies and specific Eastern European clinical trials.

Key Research Findings